The association of BMI and subclinical myocardial dysfunction in breast cancer patients after single or dual anti-HER2 targeted therapy
Abstract Background Anti-HER2 targeted therapy has significantly reduced the recurrence and death of HER2-overexpressing breast cancer patients, but might lead to cardiotoxicity. Some patients with normal myocardial function may suffer from subclinical myocardial dysfunction after anti-HER2 targeted...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-12-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-024-13377-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850282121164226560 |
|---|---|
| author | Feng Zhang Siyuan Wang Chao Yu Wenying Jin Dan He Xiaoxiao Hu Shu Wang Tiangang Zhu |
| author_facet | Feng Zhang Siyuan Wang Chao Yu Wenying Jin Dan He Xiaoxiao Hu Shu Wang Tiangang Zhu |
| author_sort | Feng Zhang |
| collection | DOAJ |
| description | Abstract Background Anti-HER2 targeted therapy has significantly reduced the recurrence and death of HER2-overexpressing breast cancer patients, but might lead to cardiotoxicity. Some patients with normal myocardial function may suffer from subclinical myocardial dysfunction after anti-HER2 targeted therapy. We sought to evaluate earlier the subclinical myocardial dysfunction in breast cancer patients after single or dual anti-HER2 targeted therapy, and identify the risk factors related to subclinical myocardiotoxicity. Methods In our study, 40 breast cancer patients after single anti-HER2 targeted therapy, and 40 breast cancer patients after dual anti-HER2 targeted therapy were enrolled. Global longitudinal strain (GLS) was measured through echocardiography. Results Seven patients in single anti-HER2 therapy group and eight patients in dual anti-HER2 therapy group had GLS lower than − 18%, suggesting subclinical myocardial dysfunction, but no difference between these two groups. Furthermore, we found that increased BMI was associated with reduction of GLS in breast cancer patients after anti-HER2 targeted therapy. Increased BMI (OR 2.683; 95% CI 1.225–5.879) was a risk factor of subclinical cardiotoxicity in dual anti-HER2 targeted therapy group. In addition, the patients with BMI ≥ 25 were more prone to have subclinical myocardial dysfunction in dual anti-HER2 therapy group compared with those with BMI ≥ 25 in single anti-HER2 therapy group. Conclusion Our results indicate dual anti-HER2 therapy does not increase the risk of subclinical myocardial dysfunction for breast cancer patients, compared with single anti-HER2 therapy. Patients with BMI ≥ 25 are more prone to have subclinical cardiotoxicity after dual anti-HER2 therapy than after single anti-HER2 therapy. Weight reduction should be the major measure to prevent subclinical myocardial dysfunction for these patients. |
| format | Article |
| id | doaj-art-e8945c6375cc4577a0372ffda9e97388 |
| institution | OA Journals |
| issn | 1471-2407 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-e8945c6375cc4577a0372ffda9e973882025-08-20T01:48:05ZengBMCBMC Cancer1471-24072024-12-012411910.1186/s12885-024-13377-1The association of BMI and subclinical myocardial dysfunction in breast cancer patients after single or dual anti-HER2 targeted therapyFeng Zhang0Siyuan Wang1Chao Yu2Wenying Jin3Dan He4Xiaoxiao Hu5Shu Wang6Tiangang Zhu7Department of Cardiology, Peking University People’s HospitalDepartment of Breast Surgery, Peking University People’s HospitalDepartment of Cardiology, Peking University People’s HospitalDepartment of Cardiology, Peking University People’s HospitalDepartment of Cardiology, Peking University People’s HospitalDepartment of Cardiology, Peking University People’s HospitalDepartment of Breast Surgery, Peking University People’s HospitalDepartment of Cardiology, Peking University People’s HospitalAbstract Background Anti-HER2 targeted therapy has significantly reduced the recurrence and death of HER2-overexpressing breast cancer patients, but might lead to cardiotoxicity. Some patients with normal myocardial function may suffer from subclinical myocardial dysfunction after anti-HER2 targeted therapy. We sought to evaluate earlier the subclinical myocardial dysfunction in breast cancer patients after single or dual anti-HER2 targeted therapy, and identify the risk factors related to subclinical myocardiotoxicity. Methods In our study, 40 breast cancer patients after single anti-HER2 targeted therapy, and 40 breast cancer patients after dual anti-HER2 targeted therapy were enrolled. Global longitudinal strain (GLS) was measured through echocardiography. Results Seven patients in single anti-HER2 therapy group and eight patients in dual anti-HER2 therapy group had GLS lower than − 18%, suggesting subclinical myocardial dysfunction, but no difference between these two groups. Furthermore, we found that increased BMI was associated with reduction of GLS in breast cancer patients after anti-HER2 targeted therapy. Increased BMI (OR 2.683; 95% CI 1.225–5.879) was a risk factor of subclinical cardiotoxicity in dual anti-HER2 targeted therapy group. In addition, the patients with BMI ≥ 25 were more prone to have subclinical myocardial dysfunction in dual anti-HER2 therapy group compared with those with BMI ≥ 25 in single anti-HER2 therapy group. Conclusion Our results indicate dual anti-HER2 therapy does not increase the risk of subclinical myocardial dysfunction for breast cancer patients, compared with single anti-HER2 therapy. Patients with BMI ≥ 25 are more prone to have subclinical cardiotoxicity after dual anti-HER2 therapy than after single anti-HER2 therapy. Weight reduction should be the major measure to prevent subclinical myocardial dysfunction for these patients.https://doi.org/10.1186/s12885-024-13377-1Breast cancerCardiotoxicityAnti-HER2 targeted therapy |
| spellingShingle | Feng Zhang Siyuan Wang Chao Yu Wenying Jin Dan He Xiaoxiao Hu Shu Wang Tiangang Zhu The association of BMI and subclinical myocardial dysfunction in breast cancer patients after single or dual anti-HER2 targeted therapy BMC Cancer Breast cancer Cardiotoxicity Anti-HER2 targeted therapy |
| title | The association of BMI and subclinical myocardial dysfunction in breast cancer patients after single or dual anti-HER2 targeted therapy |
| title_full | The association of BMI and subclinical myocardial dysfunction in breast cancer patients after single or dual anti-HER2 targeted therapy |
| title_fullStr | The association of BMI and subclinical myocardial dysfunction in breast cancer patients after single or dual anti-HER2 targeted therapy |
| title_full_unstemmed | The association of BMI and subclinical myocardial dysfunction in breast cancer patients after single or dual anti-HER2 targeted therapy |
| title_short | The association of BMI and subclinical myocardial dysfunction in breast cancer patients after single or dual anti-HER2 targeted therapy |
| title_sort | association of bmi and subclinical myocardial dysfunction in breast cancer patients after single or dual anti her2 targeted therapy |
| topic | Breast cancer Cardiotoxicity Anti-HER2 targeted therapy |
| url | https://doi.org/10.1186/s12885-024-13377-1 |
| work_keys_str_mv | AT fengzhang theassociationofbmiandsubclinicalmyocardialdysfunctioninbreastcancerpatientsaftersingleordualantiher2targetedtherapy AT siyuanwang theassociationofbmiandsubclinicalmyocardialdysfunctioninbreastcancerpatientsaftersingleordualantiher2targetedtherapy AT chaoyu theassociationofbmiandsubclinicalmyocardialdysfunctioninbreastcancerpatientsaftersingleordualantiher2targetedtherapy AT wenyingjin theassociationofbmiandsubclinicalmyocardialdysfunctioninbreastcancerpatientsaftersingleordualantiher2targetedtherapy AT danhe theassociationofbmiandsubclinicalmyocardialdysfunctioninbreastcancerpatientsaftersingleordualantiher2targetedtherapy AT xiaoxiaohu theassociationofbmiandsubclinicalmyocardialdysfunctioninbreastcancerpatientsaftersingleordualantiher2targetedtherapy AT shuwang theassociationofbmiandsubclinicalmyocardialdysfunctioninbreastcancerpatientsaftersingleordualantiher2targetedtherapy AT tiangangzhu theassociationofbmiandsubclinicalmyocardialdysfunctioninbreastcancerpatientsaftersingleordualantiher2targetedtherapy AT fengzhang associationofbmiandsubclinicalmyocardialdysfunctioninbreastcancerpatientsaftersingleordualantiher2targetedtherapy AT siyuanwang associationofbmiandsubclinicalmyocardialdysfunctioninbreastcancerpatientsaftersingleordualantiher2targetedtherapy AT chaoyu associationofbmiandsubclinicalmyocardialdysfunctioninbreastcancerpatientsaftersingleordualantiher2targetedtherapy AT wenyingjin associationofbmiandsubclinicalmyocardialdysfunctioninbreastcancerpatientsaftersingleordualantiher2targetedtherapy AT danhe associationofbmiandsubclinicalmyocardialdysfunctioninbreastcancerpatientsaftersingleordualantiher2targetedtherapy AT xiaoxiaohu associationofbmiandsubclinicalmyocardialdysfunctioninbreastcancerpatientsaftersingleordualantiher2targetedtherapy AT shuwang associationofbmiandsubclinicalmyocardialdysfunctioninbreastcancerpatientsaftersingleordualantiher2targetedtherapy AT tiangangzhu associationofbmiandsubclinicalmyocardialdysfunctioninbreastcancerpatientsaftersingleordualantiher2targetedtherapy |